IPO Plus

NSE · NATHBIOGEN

Nath Bio-Genes (India) Ltd.

₹137.43
₹261 Cr market cap
P/E
7.71
EPS
₹17.82
Book value
₹358.06
ROE
5.32%
ROCE
6.87%
Debt / equity
0.2

Revenue & net profit by period

Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.

0113226340453Mar 25Mar 25Jun 25Sep 25Dec 25Mar 26Mar 26Jun 26
Revenue (₹ Cr) Net profit (₹ Cr)

Latest period: revenue ₹323 Cr with net profit ₹33 Cr — a 10.12% net margin, versus 9.19% the period before.

Shareholding

As of 2026-09-30

45.6%
promoter holding
  • Promoter45.6%
  • Public54.21%
  • FII0.19%
  • DII0.01%

32,186 shareholders on record

Promoter holding trend

Each disclosed period, oldest to newest

45.6%45.6%Dec 24Sep 26

52-week position

Where the current price sits in its yearly band

₹126₹137₹204

The band spans 1.62× from low to high.

Risk flags

Derived from disclosed data

No flags raised by the data.

Peer comparison

Miscellaneous · ranked #183 of 552 by market cap · medians across 50 industry peers

P/E
7.71vs 42.17 peer med
P/B
0.38vs 6.5 peer med
ROE %
5.32vs 12.22 peer med
Margin %
7.9vs 13.68 peer med
CompanyMkt capP/EP/BROEMargin
National Stock Exchange Of India Ltd.₹4,72,317 Cr42.7611.2926.24%62.66%
Adani Ports & Special Economic Zone Ltd.₹4,46,185 Cr32.274.3613.33%31.98%
Eternal Limited₹3,50,452 Cr712.0611.191.58%0.63%
BSE Limited₹1,54,996 Cr50.2819.4938.76%53.09%
Vedanta Aluminium Metal Limited₹1,47,050 Cr7.786.3780.07%23.43%
GAIL (India) Ltd.₹1,22,159 Cr9.681.2613.05%7.91%
One 97 Communications Ltd.₹1,15,268 Cr137.56.935.15%8.95%
Meesho Limited₹1,08,125 Cr—25.7-21.93%-6.19%
GMR Airports Limited₹1,05,277 Cr164.580-25.64%3.13%
Multi Commodity Exchange of India Ltd.₹89,961 Cr50.0125.651.22%58.86%
Nath Bio-Genes (India) Ltd.(this company)₹261 Cr7.710.395.32%7.9%

AI analysis

AI-generated · google/gemini-2.5-flash

Nath Bio-Genes (India) Ltd. is listed with a market capitalization of Rs 311 Cr. The company reported a revenue of Rs 369.45 Cr and a profit margin of 9.82%. The earnings per share (EPS) stood at Rs 19.06. The company’s 52-week high was Rs 204 and its 52-week low was Rs 126.15.

Positives

  • +The company's revenue growth stood at 9.7% for the reported period, reaching Rs 369.45 Cr.
  • +The debt-to-equity ratio is low at 0.19, indicating limited reliance on debt financing.
  • +The promoter holding of 45.60% as of Mar 2026 suggests significant insider ownership.

Negatives

  • −The company experienced a negative net profit of -Rs 0.01 Cr in March 2026.
  • −The promoter pledge level was 13.78% as of March 31, 2026.

Financial Performance

Nath Bio-Genes (India) Ltd. reported a revenue of Rs 369.45 Cr, reflecting a revenue growth of 9.7%. The net profit for the period was not directly provided, but the profit margin was 9.82%.

Profitability & Returns

The company's profitability is indicated by an EPS of Rs 19.06 and a profit margin of 9.82%. Return on equity (ROE) was 5.32%, and return on capital employed (ROCE) was 6.87%.

Balance Sheet

Nath Bio-Genes (India) Ltd. has a debt-to-equity ratio of 0.19, with a book value per share of Rs 358.06.

Ownership & Pledges

As of March 31, 2026, promoters held 45.59% of the company's shares. Public shareholding was 54.17%, FIIs held 0.23%, and DIIs held 0.01%. A portion of the promoter's shares, specifically 13.78%, was pledged.

Quarterly Performance

In Q1 FY26 (Jun 2025), Nath Bio-Genes (India) Ltd. generated revenue of Rs 283.7 Cr and a net profit of Rs 37.28 Cr. However, in Q4 FY26 (Mar 2026), the company's net profit was -Rs 0.01 Cr, despite revenue of Rs 51.59 Cr.

Data as of — price: 2026-11-07 · financials: Jun 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.

How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.

Back to Nath Bio-Genes (India) Ltd.share price & fundamentals

Telegram App